Beneficial Effects of a Novel Bioabsorbable Polymer Coating on Enhanced Coronary Vasoconstricting Responses After Drug-Eluting Stent Implantation in Pigs in Vivo

JACC: Cardiovascular Interventions

Volumn 9, Issue 3, 2016, Pages 281-291

  Nishimiya, Kensuke ^a   Matsumoto, Yasuharu ^a   Uzuka, Hironori ^a   Ogata, Tsuyoshi ^a   Hirano, Michinori ^a   Shindo, Tomohiko ^a   Hasebe, Yuhi ^a   Tsuburaya, Ryuji ^a   Shiroto, Takashi ^a   Takahashi, Jun ^a   Ito, Kenta ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

inflammation; polymers; Rho kinase; stents

Indexed keywords

BRADYKININ; COPOLYMER; GLYCERYL TRINITRATE; HYDROXYFASUDIL; POLYCAPROLACTONE; POLYLACTIC ACID; POLYMER; RHO KINASE; SEROTONIN; BIOCOMPATIBLE COATED MATERIAL; LACTIC ACID; POLYESTER; POLYLACTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARE METAL STENT; BIOCOMPATIBILITY; CORONARY ANGIOGRAPHY; CORONARY ARTERY CONSTRICTION; DRUG ELUTING STENT; ENZYME ACTIVATION; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; IN-STENT RESTENOSIS; INFLAMMATION; MINIPIG; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; ANIMAL; BIODEGRADABLE IMPLANT; CORONARY BLOOD VESSEL; PATHOLOGY; PHYSIOLOGY; PIG; TUNICA MEDIA; VASOCONSTRICTION;

ABSORBABLE IMPLANTS; ANIMALS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY VESSELS; DRUG-ELUTING STENTS; INFLAMMATION; LACTIC ACID; MODELS, ANIMAL; POLYESTERS; POLYMERS; RHO-ASSOCIATED KINASES; SWINE; TUNICA MEDIA; VASOCONSTRICTION;

EID: 84977664744     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2015.09.041     Document Type: Article

References (35)

1. 1 Stefanini, G.G., Holmes, D.R. Jr., Drug-eluting coronary-artery stents. N Engl J Med 368 (2013), 254–265.
2. 2 Morice, M.C., Serruys, P.W., Sousa, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002), 1773–1780.
3. 3 Spaulding, C., Daemen, J., Boersma, E., Cutlip, D.E., Serruys, P.W., A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007), 989–997.
4. 4 Boden, W.E., O'Rourke, R.A., Teo, K.K., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 (2007), 1503–1516.
5. 5 Pocock, S.J., Henderson, R.A., Clayton, T., et al. Quality of life after coronary angiography or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized intervention treatment of angina. J Am Coll Cardiol 35 (2000), 907–914.
6. 6 Serruys, P.W., Chevalier, B., Dudek, D., et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 385 (2015), 43–54.
7. 7 Hamilos, M.I., Ostojic, M., Beleslin, B., et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 51 (2008), 2123–2129.
8. 8 Pendyala, L.K., Yin, X., Li, J., Chen, J.P., Chronos, N., Hou, D., The first-generation drug-eluting stents and coronary endothelial dysfunction. J Am Coll Cardiol Intv 2 (2009), 1169–1177.
9. 9 Mitsutake, Y., Ueno, T., Yokoyama, S., et al. Coronary endothelial dysfunction distal to stent of first-generation drug-eluting stents. J Am Coll Cardiol Intv 5 (2012), 966–973.
10. 10 Pendyala, L.K., Matsumoto, D., Shinke, T., et al. Nobori stent shows less vascular inflammation and early recovery of endothelial function compared with Cypher stent. J Am Coll Cardiol Intv 5 (2012), 436–444.
11. 11 Shiroto, T., Yasuda, S., Tsuburaya, R., et al. Role of Rho-kinase in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stents in pigs in vivo. J Am Coll Cardiol 54 (2009), 2321–2329.
12. 12 Tsuburaya, R., Yasuda, S., Shiroto, T., et al. Long-term treatment with nifedipine suppresses coronary hyperconstricting responses and inflammatory changes induced by paclitaxel-eluting stent in pigs in vivo: possible involvement of Rho-kinase pathway. Eur Heart J 33 (2012), 791–799.
13. 13 Nishimiya, K., Matsumoto, Y., Takahashi, J., et al. Association of adventitial vasa vasorum and inflammation with coronary hyperconstriction after drug-eluting stent implantation in pigs in vivo. Circ J 79 (2015), 1787–1798.
14. 14 Aizawa, K., Yasuda, S., Takahashi, J., et al. Involvement of rho-kinase activation in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stents in patients with coronary artery disease. Circ J 76 (2012), 2552–2560.
15. 15 Takeda, M., Shiba, N., Takahashi, J., Shimokawa, H., A case report of very late stent thrombosis with peri-stent coronary artery aneurysm and stent-related coronary vasospasm. Cardiovasc Interv Ther 28 (2013), 272–278.
16. 16 Shimokawa, H., 2014 Williams Harvey Lecture: Importance of coronary vasomotion abnormalities-from bench to bedside. Eur Heart J 35 (2014), 3180–3193.
17. 17 Kandabashi, T., Shimokawa, H., Miyata, K., et al. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1b. Circulation 101 (2000), 1319–1323.
18. 18 Shimokawa, H., Takeshita, A., Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25 (2005), 1767–1775.
19. 19 Masumoto, A., Mohri, M., Shimokawa, H., Urakami, L., Usui, M., Takeshita, A., Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105 (2002), 1545–1547.
20. 20 Virmani, R., Guagliumi, G., Farb, A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004), 701–705.
21. 21 van der Giessen, W.J., Lincoff, A.M., Schwartz, R.S., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94 (1996), 1690–1697.
22. 22 Stojkovic, S., Neskovic, A.N., Mehmedbegovic, Z., et al. Reduced sirolimus systemic exposure and improved bioresorbable polymer properties: new allies for the treatment of patients with coronary artery disease. Fundam Clin Pharmacol 29 (2015), 95–105.
23. 23 Saito, S., Valdes-Chavarri, M., Richardt, G., et al. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease). Eur Heart J 35 (2014), 2021–2031.
24. 24 Garg, S., Bourantas, C., Serruys, P.W., New concepts in the design of drug-eluting coronary stents. Nat Rev Cardiol 10 (2013), 248–260.
25. 25 Ong, P., Athanasiadis, A., Perne, A., et al. Coronary vasomotor abnormalities in patients with stable angina after successful stent implantation but without in-stent restenosis. Clin Res Cardiol 103 (2014), 11–19.
26. 26 Maseri, A., Beltrame, J.F., Shimokawa, H., Role of coronary vasoconstriction in ischemic heart disease and search for novel therapeutic targets. Circ J 73 (2009), 394–403.
27. 27 Todo, M., Park, S.D., Takayama, T., et al. Fracture micromechanisms of bioabsorbable PLLA/PCL polymer blends. Eng Fract Mech 74 (2007), 1872–1883.
28. 28 Tada, N., Virmani, R., Grant, G., et al. Polymer-free biolimus A9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv 3 (2010), 174–183.
29. 29 Matsumoto, Y., Uwatoku, T., Shimokawa, H., et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol 24 (2004), 181–186.
30. 30 Shimokawa, H., Ito, A., Fukumoto, Y., et al. Chronic treatment with interleukin-1b induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest 97 (1996), 769–776.
31. 31 Hiroki, J., Shimokawa, H., Higashi, M., et al. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol 37 (2004), 537–546.
32. 32 Lindemann, H., Sechtem, U., Ong, P., et al. Recurrent angina due to epicardial coronary spasm after successful bioresorbable vascular scaffold implantation. Circ J 79 (2015), 1853–1854.
33. 33 Kanazawa, K., Suematsu, M., Ishida, T., et al. Disparity between serotonin- and acetylcholine-provoked coronary artery spasm. Clin Cardiol 20 (1997), 146–152.
34. 34 Farb, A., Burke, A.P., Kolodgie, F.D., Virmani, R., Effect of endothelial shear stress on the progression of coronary artery disease, vascular remodeling, and in-stent restenosis in humans. Circulation 108 (2003), 1701–1706.
35. 35 Katrati, A., Mehilli, J., Dirschinger, J., et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 103 (2001), 2816–2821.